Stock Analysis

IDEAYA Biosciences Third Quarter 2022 Earnings: Beats Expectations

  •  Updated
Source: Shutterstock

IDEAYA Biosciences (NASDAQ:IDYA) Third Quarter 2022 Results

Key Financial Results
  • Revenue: US$29.7m (up 231% from 3Q 2021).
  • Net income: US$1.62m (up from US$11.6m loss in 3Q 2021).
  • Profit margin: 5.4% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue.
  • EPS: US$0.04 (up from US$0.31 loss in 3Q 2021).
NasdaqGS:IDYA Earnings and Revenue Growth November 10th 2022

All figures shown in the chart above are for the trailing 12 month (TTM) period

IDEAYA Biosciences Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with IDEAYA Biosciences (at least 2 which are a bit concerning), and understanding them should be part of your investment process.

What are the risks and opportunities for IDEAYA Biosciences?

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

View Full Analysis


  • Revenue is forecast to grow 44.16% per year


  • Shareholders have been diluted in the past year

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report

Further research on
IDEAYA Biosciences

ValuationFinancial HealthInsider TradingManagement Team